Nano-Biotechnology and Challenges of Drug Delivery System in Cancer Treatment Pathway: Review Article.

In this review, we discuss Nanotechnology models, which have been developed recently in cancer treatment. Nanotechnology manipulates matter at the atomic and molecular scale to create materials with new and advanced properties. Nano-biotechnology consists of the branches of nanotechnology that have been applied in biology (molecular and cellular genetics) and biotechnology. Nano-biotechnology allows us to put components and compounds into cells and build new materials using new methods like assembly. Cancer is a disease caused by an uncontrolled division of abnormal cells in a part of the body. Its therapeutic methods include chemotherapy, radiation, or surgery, but the effects of these techniques are not only on tumor tissue and may affect healthy tissues. Nano-Biotech applications regarding cancer include drug delivery, treatment, and foresight therapy. This review article aims to obtain a proper mentality of the current technologies of Nano-biotechnology for cancer treatment.

A randomized controlled trial on the efficacy, safety, and pharmacokinetics of metformin in severe traumatic brain injury.

OBJECTIVE: Traumatic brain injury (TBI) is a leading cause of morbidity and mortality worldwide. Metformin is reported to have pleiotropic neuroprotective effects through anti-inflammatory, antioxidative, and anti-ischemic activity, and improvements in vascular hemodynamics and endothelial function. The aim of this study is to examine the efficacy and safety of metformin therapy in severe TBI patients. METHODS: This single-blind, parallel-group, randomized controlled trial enrolled adult TBI patients. Of 158 trauma patients assessed, 30 met the eligibility criteria and were randomly allocated in a one-to-one ratio to receive 1 g metformin every 12 h for five consecutive days (intervention group) or to usual management only (control group). For efficacy analysis, temporal profiles of serum levels of S100b, neutrophil to lymphocyte ratio (NLR), and glial fibrillary acidic protein (GFAP) were assessed. For pharmacokinetic analysis, serum concentrations of metformin were evaluated in the intervention group. RESULTS: The two study groups were similar in terms of demographics, baseline clinical characteristics, and on-admission biomarkers' serum levels. Longitudinal analysis of S100b and NLR levels showed statistically significant declines in values toward normal levels in the intervention group (p values of < 0.001 and 0.030, respectively), different from the profiles of the control group (p values of 0.074 and 0.645, respectively). Pharmacokinetic analysis demonstrated that metformin absorption is delayed in TBI patients. No events of hypoglycemia and lactic acidosis occurred. CONCLUSIONS: Metformin could potentially be an effective and safe therapeutic intervention in patients with severe TBI. Large-scale, multicentre studies are needed to confirm our encouraging results.